Next Article in Journal
Immune Reconstitution Inflammatory Syndrome with Recurrent Paradoxical Cerebellar HIV-Associated Progressive Multifocal Leukoencephalopathy
Next Article in Special Issue
Ginger Is a Potential Therapeutic for Chronic Toxoplasmosis
Previous Article in Journal
Spatiotemporal and Quantitative Monitoring of the Fate of ‘Candidatus Phytoplasma Solani’ in Tomato Plants Infected by Grafting
Previous Article in Special Issue
Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pathogens
Volume 10
Issue 7
10.3390/pathogens10070812
pathogens-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Study Protocol

Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol

by
Fernando Salvador
1,*,†,
Ana Lucas-Dato
2,†,
Silvia Roure
3,†,
Marta Arsuaga
4,†,
Asunción Pérez-Jacoiste
5,†,
Magdalena García-Rodríguez
6,†,
José A. Pérez-Molina
7,†,
Dora Buonfrate
8,†,
José María Saugar
9,† and
Israel Molina
1,†
1
Infectious Diseases Department, Vall d’Hebron University Hospital, PROSICS Barcelona, 08035 Barcelona, Spain
2
Internal Medicine Department, Hospital Vega Baja, 03314 Orihuela, Spain
3
Infectious Diseases Department, North Metropolitan International Health Unit, Germans Trias i Pujol University Hospital, PROSICS North Metropolitan, 08916 Badalona, Spain
4
Tropical Medicine Unit, Infectious Diseases Department, La Paz-Carlos III University Hospital, 28046 Madrid, Spain
5
Internal Medicine Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
6
Infectious Diseases Department, Hospital General Universitario de Valencia, 46014 Valencia, Spain
7
National Referral Unit for Tropical Diseases, Infectious Diseases Department, Hospital Ramón y Cajal, IRYCIS, 28034 Madrid, Spain
8
Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, 37024 Verona, Italy
9
Parasitology Department, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28222 Madrid, Spain
*
Author to whom correspondence should be addressed.
†
On behalf of the ImmunoStrong Study Group.
Pathogens 2021, 10(7), 812; https://doi.org/10.3390/pathogens10070812
Submission received: 27 May 2021 / Revised: 14 June 2021 / Accepted: 23 June 2021 / Published: 27 June 2021
(This article belongs to the Special Issue Optimizing Treatment for Parasitic Infections)
Versions Notes

Abstract

Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients.
Keywords: Strongyloides stercoralis; immunosuppression; ivermectin; PCR; population pharmacokinetics Strongyloides stercoralis; immunosuppression; ivermectin; PCR; population pharmacokinetics

Share and Cite

MDPI and ACS Style

Salvador, F.; Lucas-Dato, A.; Roure, S.; Arsuaga, M.; Pérez-Jacoiste, A.; García-Rodríguez, M.; Pérez-Molina, J.A.; Buonfrate, D.; Saugar, J.M.; Molina, I. Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol. Pathogens 2021, 10, 812. https://doi.org/10.3390/pathogens10070812

AMA Style

Salvador F, Lucas-Dato A, Roure S, Arsuaga M, Pérez-Jacoiste A, García-Rodríguez M, Pérez-Molina JA, Buonfrate D, Saugar JM, Molina I. Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol. Pathogens. 2021; 10(7):812. https://doi.org/10.3390/pathogens10070812

Chicago/Turabian Style

Salvador, Fernando, Ana Lucas-Dato, Silvia Roure, Marta Arsuaga, Asunción Pérez-Jacoiste, Magdalena García-Rodríguez, José A. Pérez-Molina, Dora Buonfrate, José María Saugar, and Israel Molina. 2021. "Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol" Pathogens 10, no. 7: 812. https://doi.org/10.3390/pathogens10070812

APA Style

Salvador, F., Lucas-Dato, A., Roure, S., Arsuaga, M., Pérez-Jacoiste, A., García-Rodríguez, M., Pérez-Molina, J. A., Buonfrate, D., Saugar, J. M., & Molina, I. (2021). Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol. Pathogens, 10(7), 812. https://doi.org/10.3390/pathogens10070812

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop